Skip to main content
Premium Trial:

Request an Annual Quote

Newly Public Helicos Reports Widening Q2 Loss Amid Rising R&D Expenses

NEW YORK (GenomeWeb News) — In its first quarterly earnings report since its initial public offering in May, Helicos today said R&D spending and net loss both nearly doubled compared to the prior-year period.
Total receipts for the three months ended June 30 were $143,000, while the company claimed no revenue for the second quarter of 2006. The company said all of its revenue for the quarter, and for the year to date, came from grants from the National Institutes of Health.
R&D spending nearly doubled for the second quarter, rising to $5.3 million from $2.9 million in the second quarter of 2006.
Net loss also almost doubled compared to the year-ago period, to $8.1 million from $4.2 million in the comparable period of 2006.
As of June 30, Helicos had $64 million in combined cash and cash equivalents. The company said it expects to have around $40 million in cash at the end of fiscal 2007, and its net cash use on the year also is expected to be roughly $40 million.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.